ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Sun Pharma's board approved issuing unsecured Non-Convertible Debentures up to ₹10,000 Crore. Additionally, Independent Director Mr. Gautam Doshi resigned from the company's board.
Sun Pharmaceutical Industries Limited will hold a board meeting on October 12, 2026, to consider a proposed debt issue for fund raising.
Sun Pharma scheduled a board meeting on 12 October 2026 to consider issuing NCDs worth up to ₹15,000 Crore on a private placement basis.
Sun Pharma established an endowed professorship at Icahn School of Medicine at Mount Sinai with a $2.5 million grant to advance dermatology research and education.
Sun Pharma reported positive two-year clinical data for its LEQSELVI alopecia areata treatment, presented at the 2026 EADV Congress, highlighting sustained safety and efficacy.
Sun Pharma signed a global licensing and commercialization agreement with LIB Therapeutics for lerodalcibep, excluding US and China, strengthening its innovative medicines portfolio.
Sun Pharmaceutical Industries Ltd published voting results for a Postal Ballot. Shareholders approved the reclassification of three promoter group members to the public category.
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharma attended a White House signing ceremony, committing to Most Favored Nation pricing for U.S. Medicaid programs and future innovative medicine launches.
Sun Pharma seeks shareholder approval via postal ballot to reclassify three members of the 'Promoter Group' to the 'Public' category, effective upon requisite approval.
Sun Pharma announced a favorable court ruling in the US Lipitor antitrust litigation, which brings the long-standing matter substantially to a close.
Sun Pharmaceutical Industries Ltd received no-objection letters from the NSE and BSE to reclassify certain members from the promoter group to the public category.
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
CRISIL reaffirmed Sun Pharmaceutical Industries' long-term bank facilities rating at 'CRISIL AAA/Stable'. The 'Rating Watch with Developing Implications' status has been officially removed.
Sun Pharma delivered strong double-digit growth led by India and global specialty medicines, though US generics face erosion and increased competition.